UNSPSC 51161548: Nepadutant

This classification denotes an anti-asthmatic agent with the molecular formula C45H58N10O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XW59TYL1XH, chemically known as men-11,420 but generally known as nepadutant, which bears US NIH Compound Identifier 3086682. European Medicines Agency schedules Nepadutant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09196MIG.

UNSPSC 51161548 Nepadutant, a Commodity code, covers pharmaceutical products supplied through cooperative purchasing alliances to state and local government facilities. State and local governments procure generic pharmaceuticals and over-the-counter products under this code through multi-state cooperative vehicles, with recent activity driven by purchasing alliances rather than individual jurisdictions. The scope includes manufacturers supplying finished pharmaceutical products with specific National Drug Codes (NDC), SKUs, UPCs, and packaging configurations to authorized wholesalers serving participating state and local facilities. Products must meet current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, with expiration dates of at least one year from manufacture and minimum six-month shelf life. Vendors establish pricing through fixed-price, net-price, or WAC-minus structures, maintain contractual relationships with multiple authorized wholesalers with chargeback systems in place, and comply with electronic data interchange (EDI) capability requirements. Contract administration involves payment of a 3 percent administrative fee on all purchases and performance penalties ranging from $200 to $1,500 per violation.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026. The MMCAP procurement covers participating state and local government facilities across multiple states including Oregon. Awarded vendors will be provided to three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with agreements effective July 1, 2026. The RFP weights price competitiveness at 75 percent of evaluation, with the remaining 25 percent distributed among fixed pricing (10 percent), administrative compliance and EDI capability (5 percent each), and administrative fee agreement (5 percent). Contract terms run two years for new responders with optional extensions at MMCAP's sole discretion; incumbent vendors' amendments align with existing agreement expiration dates through June 30, 2028.